174 related articles for article (PubMed ID: 16306351)
1. A polygenic model of the metabolic syndrome with reduced circulating and intra-adipose glucocorticoid action.
Morton NM; Densmore V; Wamil M; Ramage L; Nichol K; Bünger L; Seckl JR; Kenyon CJ
Diabetes; 2005 Dec; 54(12):3371-8. PubMed ID: 16306351
[TBL] [Abstract][Full Text] [Related]
2. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of adipose 11beta-hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease.
Morton NM; Ramage L; Seckl JR
Endocrinology; 2004 Jun; 145(6):2707-12. PubMed ID: 15044372
[TBL] [Abstract][Full Text] [Related]
4. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Masuzaki H; Flier JS
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
[TBL] [Abstract][Full Text] [Related]
5. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
6. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice.
Morton NM; Paterson JM; Masuzaki H; Holmes MC; Staels B; Fievet C; Walker BR; Flier JS; Mullins JJ; Seckl JR
Diabetes; 2004 Apr; 53(4):931-8. PubMed ID: 15047607
[TBL] [Abstract][Full Text] [Related]
7. Carbenoxolone treatment ameliorated metabolic syndrome in WNIN/Ob obese rats, but induced severe fat loss and glucose intolerance in lean rats.
Prasad Sakamuri SS; Sukapaka M; Prathipati VK; Nemani H; Putcha UK; Pothana S; Koppala SR; Ponday LR; Acharya V; Veetill GN; Ayyalasomayajula V
PLoS One; 2012; 7(12):e50216. PubMed ID: 23284633
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue.
Seckl JR; Morton NM; Chapman KE; Walker BR
Recent Prog Horm Res; 2004; 59():359-93. PubMed ID: 14749510
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
[TBL] [Abstract][Full Text] [Related]
10. A transgenic model of visceral obesity and the metabolic syndrome.
Masuzaki H; Paterson J; Shinyama H; Morton NM; Mullins JJ; Seckl JR; Flier JS
Science; 2001 Dec; 294(5549):2166-70. PubMed ID: 11739957
[TBL] [Abstract][Full Text] [Related]
11. Reduced adipose glucocorticoid reactivation and increased hepatic glucocorticoid clearance as an early adaptation to high-fat feeding in Wistar rats.
Drake AJ; Livingstone DE; Andrew R; Seckl JR; Morton NM; Walker BR
Endocrinology; 2005 Feb; 146(2):913-9. PubMed ID: 15550507
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoid-induced insulin resistance is related to macrophage visceral adipose tissue infiltration.
Do TTH; Marie G; Héloïse D; Guillaume D; Marthe M; Bruno F; Marion B
J Steroid Biochem Mol Biol; 2019 Jan; 185():150-162. PubMed ID: 30145227
[TBL] [Abstract][Full Text] [Related]
13. 11-Dehydrocorticosterone causes metabolic syndrome, which is prevented when 11β-HSD1 is knocked out in livers of male mice.
Harno E; Cottrell EC; Keevil BG; DeSchoolmeester J; Bohlooly-Y M; Andersén H; Turnbull AV; Leighton B; White A
Endocrinology; 2013 Oct; 154(10):3599-609. PubMed ID: 23832962
[TBL] [Abstract][Full Text] [Related]
14. Tissue-specific regulation of 11β hydroxysteroid dehydrogenase type-1 mRNA expressions in Cushing's syndrome mouse model.
Nishiyama M; Iwasaki Y; Nakayama S; Okazaki M; Taguchi T; Tsuda M; Makino S; Fujimoto S; Terada Y
Steroids; 2022 Jul; 183():109021. PubMed ID: 35339573
[TBL] [Abstract][Full Text] [Related]
15. Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study.
Paulmyer-Lacroix O; Boullu S; Oliver C; Alessi MC; Grino M
J Clin Endocrinol Metab; 2002 Jun; 87(6):2701-5. PubMed ID: 12050237
[TBL] [Abstract][Full Text] [Related]
16. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients.
Desbriere R; Vuaroqueaux V; Achard V; Boullu-Ciocca S; Labuhn M; Dutour A; Grino M
Obesity (Silver Spring); 2006 May; 14(5):794-8. PubMed ID: 16855188
[TBL] [Abstract][Full Text] [Related]
17. Role of glucocorticoids in the physiopathology of excessive fat deposition and insulin resistance.
Asensio C; Muzzin P; Rohner-Jeanrenaud F
Int J Obes Relat Metab Disord; 2004 Dec; 28 Suppl 4():S45-52. PubMed ID: 15592486
[TBL] [Abstract][Full Text] [Related]
18. Effect of hyperlipidemia on 11β-hydroxysteroid-dehydrogenase, glucocorticoid receptor, and leptin expression in insulin-sensitive tissues of cats.
Sieber-Ruckstuhl NS; Zini E; Osto M; Franchini M; Boretti FS; Meli ML; Sigrist B; Lutz TA; Reusch CE
Domest Anim Endocrinol; 2010 Nov; 39(4):222-30. PubMed ID: 20688460
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.
Wake DJ; Walker BR
Endocrine; 2006 Feb; 29(1):101-8. PubMed ID: 16622297
[TBL] [Abstract][Full Text] [Related]
20. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease.
Morton NM
Mol Cell Endocrinol; 2010 Mar; 316(2):154-64. PubMed ID: 19804814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
